An interventional study of TMS and control group in Cataract Surgery Experience, sponsored by Shanghai High Myopia Study Group. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Shanghai High Myopia Study Group · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.
Among the 184 studies in Cataract with a site in China, this one is the 28th largest by planned enrollment of the 111 interventional ones that give a count, is one of 15 that started in 2025, is one of 104 with no phase, reaches primary completion later than 36 of the 48 other live ones, and was the 143rd registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18–90
Nanfang Hospital, Southern Medical University · Sites in China
Ages 40–85
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–90
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 50–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 90 across the 111 interventional studies, 120 across the 73 observational. Of the 80 that completed or were terminated, 9 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
Shanghai High Myopia Study Group is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Shanghai High Myopia Study Group has 3 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
7 of the studies in Cataract with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07713069Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOCT-PRO Model vs. Clinicians: Cataract Surgery Outcome Prediction | 2026-11-30 |
| NCT02182921Evidence Based Cataract Study GroupEvaluation of Cataract Surgery Outcome | 2026-12 |
| NCT07550907Zhongshan Ophthalmic Center, Sun Yat-sen UniversityThe Impact of Surgical Procedures on Postoperative Outcomes in Cataract Phacoemulsification and Analysis of Related Factors | 2026-12-31 |
| NCT07733154The Hong Kong Polytechnic UniversityAI-Driven IOL Prediction Using SS-OCT Biometry | 2027-03-20 |
| NCT07126470Zhongshan Ophthalmic Center, Sun Yat-sen UniversityImpact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 184 studies in Cataract with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients after cataract surgery. The main question it aims to answer is:
Participants will
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
TMS treatment indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
Procedure: TMS
The sham group will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
Procedure: control group
TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
Visual acuity
Time frame: From enrollment to the end of treatment at 2 weeks
Visual field
Time frame: From enrollment to the end of treatment at 2 weeks
Visual quality
Include objective visual quality (contrast sensitivity) and subjective visual quality (visual function questionnaire score).
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 24 months is above that.
Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Oct 2024 → Oct 2025, primary completion Oct 2025 → Oct 2027 and completion Oct 2026 → Oct 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai High Myopia Study Group